Efficacy of Bortezomib Combined with Thalidomide and Dexamethasone in the Treat-ment of Autologous Stem Cell Transplantation in Multiple Myeloma:A Meta-analysis
10.3870/j.issn.1004-0781.2016.03.025
- VernacularTitle:硼替佐米联合沙利度胺和地塞米松治疗自体造血干细胞移植多发性骨髓瘤的Meta分析
- Author:
Haixue WANG
;
Yun YE
- Publication Type:Journal Article
- Keywords:
Bortezomib;
Dexamethasone;
Thalidomide;
Myeloma,multiple;
Transplantation,stem cell;
Meta-analysis
- From:
Herald of Medicine
2016;(3):308-313
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of bortezomib combined with dexamethasone and thalidomide in the treatment of autologous stem cell transplantation ( ASCT) in multiple myeloma ( MM) . Methods The randomized con-trolled trials ( RCTs) on combined therapy with bortezomib,dexamethasone and thalidomide for ASCT in MM were retrieved from Pubmed,Medline,the Cochrane Library,CNKI,VIP and Wanfang databases (published until December 2014).The method of the Cochrane systematic review was used to evaluate the quality of the included RCTs and the Review Manager 5.3.5 software was em-ployed for Meta-analysis. Results Five RCTs involving 1 271 patients were included.The meta analysis results showed that the complete remission ( CR) rate,near-CR rate and total effective rate were significantly higher after combined treatment with borte-zomib,dexamethasone and thalidomide when compared with those in other combination therapies [CR+nCR, RR=1.50,95%CI (1.16,1.94),P=0.002;the total effective rate,RR=1.13,95%CI (1.03,1.24),P=0.009].In terms of safety,the grade 3/4 ad-verse events were significantly increased in the group of combined therapy with bortezomib,dexamethasone and thalidomide [ RR=1.29,95%CI (1.05,1.59),P=0.02]. Conclusion Bortezomib combined with thalidomide and dexamethasone for the treat-ment of ASCT in MM can significantly improve the CR+nCR and the total effective rate,but it also increases the incidence of the overall adverse events at the same time.
